Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that the Company will participate in two upcoming healthcare conferences.
- Thursday, September 7th, the Company will host investor meetings at Citi’s 18th Annual BioPharma Conference in Boston, MA.
- Wednesday, September 13th at 10:50am ET/7:50am PT, the Company will participate in a fireside chat and also host investor meetings at the 21st Annual Morgan Stanley Global Healthcare Conference in New York, NY.
A live webcast of the Morgan Stanley fireside chat will be available in the investor relations section of the Company’s website at https://ir.alpineimmunesciences.com/events and a replay will be available on the Company's website for 90 days following the event.
About Alpine Immune Sciences
Alpine Immune Sciences is committed to leading a new wave of immune therapeutics. With world-class research and development capabilities, a highly productive scientific platform, and a proven management team, Alpine is seeking to create first- or best-in-class multifunctional immunotherapies via unique protein engineering technologies to improve patients’ lives. Alpine has entered into strategic collaborations with leading global biopharmaceutical companies and has a diverse pipeline of clinical and preclinical candidates in development. For more information, visit www.alpineimmunesciences.com. Follow @AlpineImmuneSci on Twitter and LinkedIn.